Antimicrobial peptides with therapeutic potential from skin secretions of the Marsabit clawed frog Xenopus borealis (Pipidae)

Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP
Milena MechkarskaJ Michael Conlon

Abstract

Nine peptides with differential growth inhibitory activity against Escherichia coli and Staphylococcus aureus were isolated from norepinephrine-stimulated skin secretions of the tetraploid frog Xenopus borealis Parker, 1936 (Pipidae). Structural characterization of the peptides demonstrated that they were orthologous to magainin-2 (1 peptide), peptide glycine-leucine-amide, PGLa (2 peptides), caerulein-precursor fragments, CPF (4 peptides), and xenopsin-precursor fragments, XPF (2 peptides), previously isolated from Xenopus laevis and X. amieti. In addition, a second magainin-related peptide (G**KFLHSAGKFGKAFLGEVMIG) containing a two amino acid residue deletion compared with magainin-2 was identified that had only weak antimicrobial activity. The peptide with the greatest potential for development into a therapeutically valuable anti-infective agent was CPF-B1 (GLGSLLGKAFKIGLKTVGKMMGGAPREQ) with MIC=5 microM against E. coli, MIC=5 microM against S. aureus, and MIC=25 microM against Candida albicans, and low hemolytic activity against human erythrocytes (LC(50)>200 microM). This peptide was also the most abundant antimicrobial peptide in the skin secretions. CPF-B1 was active against clinical isolates of the nosocomial pathogens...Continue Reading

References

Feb 1, 1992·Antimicrobial Agents and Chemotherapy·R BessalleM Fridkin
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M Zasloff
Apr 1, 1987·The Biochemical Journal·M G GiovanniniD H Williams
Dec 10, 2002·Current Opinion in Chemical Biology·Andrea C Rinaldi
Mar 17, 2004·Peptides·Jon-Paul S Powers, Robert E W Hancock
Aug 25, 2004·Molecular Phylogenetics and Evolution·Ben J EvansDavid C Cannatella
Feb 1, 2005·The Lancet Infectious Diseases·S Ragnar NorrbyUNKNOWN European Society of Clinical Microbiology and Infectious Diseases
May 23, 2006·International Journal of Antimicrobial Agents·Tibor PálJ Michael Conlon
Jun 15, 2007·Methods : a Companion to Methods in Enzymology·J Michael ConlonJérôme Leprince
Nov 17, 2007·Nature Reviews. Microbiology·Lenie DijkshoornHarald Seifert
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Jordi Vila, Jerónimo Pachón
Jul 1, 2008·Expert Review of Anti-infective Therapy·Thomas D Gootz, Andrea Marra
Jul 10, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter J SebenyKyle Petersen
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Nov 22, 2008·The Lancet Infectious Diseases·Drosos E Karageorgopoulos, Matthew E Falagas
Mar 18, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J GarauS Harbarth
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·David M Livermore
Aug 15, 2009·Nature Reviews. Microbiology·Henry F Chambers, Frank R Deleo
Dec 4, 2009·Current Diabetes Reports·Frank L BowlingAndrew J M Boulton
Jan 23, 2010·Methods in Molecular Biology·Lijuan Zhang, Timothy J Falla
Mar 9, 2010·Lancet·Frank R DeLeoHenry F Chambers
Apr 3, 2010·British Medical Bulletin·Fiona J Cooke, Nicholas M Brown

❮ Previous
Next ❯

Citations

Aug 13, 2013·PLoS Genetics·Kim RoelantsFranky Bossuyt
Aug 3, 2014·Comparative Biochemistry and Physiology. Part D, Genomics & Proteomics·Milena MechkarskaJ Michael Conlon
Feb 12, 2011·European Biophysics Journal : EBJ·Mohammed Akhter HossainJ Michael Conlon
Dec 3, 2014·Comparative Biochemistry and Physiology. Part D, Genomics & Proteomics·J Michael ConlonHubert Vaudry
May 12, 2011·Cellular and Molecular Life Sciences : CMLS·J Michael Conlon
Nov 1, 2011·General and Comparative Endocrinology·J Michael ConlonJay D King
Apr 19, 2011·Comparative Biochemistry and Physiology. Part D, Genomics & Proteomics·Milena MechkarskaJ Michael Conlon
Jan 5, 2011·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·J Michael ConlonKoji Takada
Oct 20, 2010·Peptides·Enrico König, Olaf R P Bininda-Emonds
Sep 4, 2014·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Douglas Oscar Ceolin MarianoDaniel Carvalho Pimenta
Dec 3, 2014·Peptides·Enrico KönigChris Shaw
Jun 13, 2016·Comparative Biochemistry and Physiology. Part D, Genomics & Proteomics·Laurent CoquetJ Michael Conlon
Jan 25, 2017·The Journal of Endocrinology·Srividya VasuPeter R Flatt
May 11, 2020·Microbial Pathogenesis·Alireza NeshaniAbolfazl Jahangiri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.